Diagnosing valvular heart disease
|
|
Sukhjinder Nijjer is specialty registrar,
cardiology, at the Royal Brompton Hospital, London
Jasdeep Gill is
a foundation
doctor, general medicine, at Southampton General Hospital
Sandeep
Nijjer is a clinical lecturer at the University of London School
of Pharmacy |
|
CNRI/SPL

A prosthetic heart valve (“caged ball” type)
replacing the mitral valve |
SUMMARY
Valvular heart disease (VHD) is common and it is essential that hospital
pharmacists understand the disease and the role of
pharmacotherapy in its treatment and prevention.
The heart is composed of four chambers (two atria and two ventricles) and
contains four valves (mitral and aortic valves on the left, tricuspid and
pulmonary valves on the right).
The valves prevent blood flowing backwards
within the systemic (left side) and pulmonary (right side) circulations.
Many disease processes affect the cardiac valves. Disease may cause valve
stenosis (narrowing) or regurgitation (blood leaking in the wrong direction),
with haemodynamic consequences.
Acute or subacute infection, most commonly
bacterial endocarditis, can destroy heart valves, as can connective tissue
diseases. Diseases of the chambers can also affect the valves and cause
functional disease.
Thirty years ago, the most common cause of VHD in people under the age
of 60 years was rheumatic heart disease — an immunological reaction
to streptococcal infection. Widespread antibiotic use has reduced the incidence
of rheumatic heart disease, and the most common form of VHD is now degenerative
valvular disease in elderly patients.
Comorbidity is common; atherosclerosis, renal impairment and chronic
obstructive pulmonary disease are the most frequent conditions found
in VHD patients.
Increasing numbers of patients are now undergoing valve replacement operations,
and optimising cardiac function in patients awaiting these operations
has become an important aspect of patient care. Following surgery, there
is
a strong emphasis on anti-coagulation monitoring and antibiotic prophylaxis
against endocarditis.
This article will describe how the six most common forms of VHD are managed.
A second
article (p127) focuses on anticoagulation and prophylaxis of endocarditis.
Diagnosing valvular
heart disease
Patients with VHD can present with
a variety of symptoms. These typically include breathlessness, lethargy,
chest pain or collapse.
Echocardiography is the investigation of choice, producing two-dimensional
images of cardiac anatomy and dysfunctional valves. However, echocardiography
is performer dependent and serial studies are required to aid decision
making. Magnetic resonance imaging can complement echocardiographic
data.
Colour Doppler and Doppler studies are used to assess the haemodynamic
consequences of the disease (eg, the valve area, the velocity of flow
across a valve and the effective regurgitant orifice area). Some specialist
centres also use computerised topography to assess valvular calcification
and exclude concomitant coronary artery disease. |
|